USA flag logo/image

An Official Website of the United States Government

Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R44AI081396
Solicitation Year:
2011
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
TSRL, INC.
540 AVIS DR, STE A ANN ARBOR, MI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability
Agency: HHS
Contract: 2R44AI081396-02
Award Amount: $2,585,246.00
 

Abstract:

DESCRIPTION (provided by applicant): Virally-encoded neuraminidase plays a key role in the life-cycle of the influenza virus. A class of anti-influenza drugs that inhibits the action of neuraminidase has garnered increasing interest in the pharmaceutical industry due to their selectivity and potency. The inhibitors are transition state analogs of the enzyme substrate, sialic acid, and are highly efficacious in in vitro and in vivo studies, with IC50 values in the nM range. However these drugs are very polarand consequently have poor oral bioavailability. At TSRL, we have a developed an amino acid prodrug strategy that targets intestinal transporters for enhanced uptake. Subsequent activation of the absorbed prodrug can then occur either through targeted enzymatic hydrolysis of the prodrug or chemical breakdown of the prodrug to the activate parent compound. This strategy is based on a molecular mechanistic understanding of the transport and activation pathways in cells and tissues and the interaction of prodrug structures with these pathways. In this proposal, we have developed novel amino acid prodrugs of two neuraminidase inhibitors and provide strong supporting data showing that these prodrugs are actively transported by intestinal transporter and are wellabsorbed. We show that through our approach, we can boost the oral availability of selected neuraminidase inhibitors to an extent that they are effective in animal models of influenza and have high potential to be developed as oral drug products. In the current project, we propose to select a lead neuraminidase inhibitor by in vivo (mouse and ferret) testing of the developed series of compounds against a range of influenza strains, including recent H1N1 isolates, seasonal flu isolates, drug resistant virusand high pathogenic strains of the virus. Our molecular mechanistic approach to prodrug design has enormous potential for the development of orally effective neuraminidase inhibitors. PUBLIC HEALTH RELEVANCE: TSRL has developed an approach to improve the oral bioavailability of anti-influenza drugs, thus making them suitable for oral delivery. We propose to synthesize and test a series of these compounds for their potential as oral anti-influenza agents. Ultimately, this approach may increase thenumber of potent anti-virus compounds that are available for therapeutic and prophylactic treatment of influenza.

Principal Investigator:

John M. Hilfinger
734-663-4233
jhilfinger@tsrlinc.com

Business Contact:

John M. Hilfinger
734-663-4233
jhilfinger@tsrlinc.com
Small Business Information at Submission:

TSRL, INC.
540 AVIS DR, STE A ANN ARBOR, MI -

EIN/Tax ID: 138265182
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No